Last reviewed · How we verify
Huntington's chorea — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Austedo | DEUTETRABENAZINE | Teva | Synaptic vesicular amine transporter | 2017-01-01 | ||
| Xenazine | TETRABENAZINE | Bausch Health | Vesicular Monoamine Transporter 2 Inhibitor [EPC] | Synaptic vesicular amine transporter | 2008-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bausch Health · 1 drug in Huntington's chorea
- Teva · 1 drug in Huntington's chorea
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Huntington's chorea:
- Huntington's chorea treatment updates — RSS
- Huntington's chorea treatment updates — Atom
- Huntington's chorea treatment updates — JSON
Cite this brief
Drug Landscape (2026). Huntington's chorea — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/huntington-s-chorea. Accessed 2026-06-10.
Related
- Huntington's chorea full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing